CA2232410C - Procedes ameliores de production de vaccins polyvalents a sous-unites de proteosomes complexees de maniere non covalente - Google Patents
Procedes ameliores de production de vaccins polyvalents a sous-unites de proteosomes complexees de maniere non covalente Download PDFInfo
- Publication number
- CA2232410C CA2232410C CA002232410A CA2232410A CA2232410C CA 2232410 C CA2232410 C CA 2232410C CA 002232410 A CA002232410 A CA 002232410A CA 2232410 A CA2232410 A CA 2232410A CA 2232410 C CA2232410 C CA 2232410C
- Authority
- CA
- Canada
- Prior art keywords
- proteosome
- preparation
- vaccine according
- amphiphilic determinant
- amphiphilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 238000004519 manufacturing process Methods 0.000 title abstract description 19
- 229940031626 subunit vaccine Drugs 0.000 title description 4
- 229960005486 vaccine Drugs 0.000 claims abstract description 114
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 96
- 239000002158 endotoxin Substances 0.000 claims abstract description 95
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- 239000003599 detergent Substances 0.000 claims abstract description 39
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 28
- 238000011026 diafiltration Methods 0.000 claims abstract description 20
- 241000607760 Shigella sonnei Species 0.000 claims abstract description 18
- 241000606999 Plesiomonas shigelloides Species 0.000 claims abstract description 14
- 229940031348 multivalent vaccine Drugs 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 238000012544 monitoring process Methods 0.000 claims abstract description 6
- 241000607762 Shigella flexneri Species 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 18
- 239000012466 permeate Substances 0.000 claims description 18
- 239000012465 retentate Substances 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 13
- 241000607768 Shigella Species 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical group CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims description 12
- 239000012510 hollow fiber Substances 0.000 claims description 10
- 239000011148 porous material Substances 0.000 claims description 8
- 229940115939 shigella sonnei Drugs 0.000 claims description 7
- 241000588653 Neisseria Species 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 2
- 241000607766 Shigella boydii Species 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 241000607000 Plesiomonas Species 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 abstract description 15
- 238000005516 engineering process Methods 0.000 abstract description 15
- 238000013341 scale-up Methods 0.000 abstract description 9
- 238000011109 contamination Methods 0.000 abstract description 8
- 230000007423 decrease Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 230000000536 complexating effect Effects 0.000 description 16
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 208000004429 Bacillary Dysentery Diseases 0.000 description 10
- 241000147000 Shigella flexneri 2a Species 0.000 description 10
- 206010040550 Shigella infections Diseases 0.000 description 10
- 201000005113 shigellosis Diseases 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 101710116435 Outer membrane protein Proteins 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 231100000518 lethal Toxicity 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000003134 recirculating effect Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000011012 sanitization Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010028921 Lipopeptides Proteins 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 241001212279 Neisseriales Species 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 229910001679 gibbsite Inorganic materials 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002011 intestinal secretion Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DWHCYDWXLJOFFO-UHFFFAOYSA-N 4-(5-phenylthiophen-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(C=2C=CC=CC=2)S1 DWHCYDWXLJOFFO-UHFFFAOYSA-N 0.000 description 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241001233242 Lontra Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000100287 Membras Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- -1 liposaccharides Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un procédé pour préparer des vaccins polyvalents à protéosomes-déterminants amphiphiles, convenant à une administration parentérale ou mucosale par diafiltration ou ultrafiltration. Les déterminants amphiphiles comprennent des lipopolysaccharides de bactéries Gram négatif, par exemple de S. flexneri, P. shigelloides et S. sonnei. Les protéosomes sont obtenus à partir des méningocoques du type 2b du groupe B. Les complexes protéosomes actifs-déterminants amphiphiles (complexes non covalents) du vaccin sont obtenus par diafiltration ou par ultrafiltration, pour éliminer le détergent. L'utilisation de la diafiltration ou de l'ultrafiltration diminue le temps de traitement et les risques de contamination. Egalement, on peut travailler à température ambiante et on peut facilement augmenter la taille des installations. En plus, le procédé permet une surveillance continue et sûre du dialysat, ce qui améliore l'efficacité de tout le procédé. La durée de la dialyse pour la production d'un lot de vaccin passe de plus de 7-10 jours à moins de 72 heures et habituellement moins de 48 ou 24 heures. L'utilisation du procédé optimise la présence de chaque composant antigénique dans la préparation de vaccins polyvalents.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US385995P | 1995-09-18 | 1995-09-18 | |
US60/003,859 | 1995-09-18 | ||
PCT/US1996/015002 WO1997010844A1 (fr) | 1995-09-18 | 1996-09-18 | Procedes ameliores de production de vaccins polyvalents a sous-unites de proteosomes complexees de maniere non covalente |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2232410A1 CA2232410A1 (fr) | 1997-03-27 |
CA2232410C true CA2232410C (fr) | 2003-06-17 |
Family
ID=21707938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002232410A Expired - Lifetime CA2232410C (fr) | 1995-09-18 | 1996-09-18 | Procedes ameliores de production de vaccins polyvalents a sous-unites de proteosomes complexees de maniere non covalente |
Country Status (20)
Country | Link |
---|---|
US (1) | US6476201B1 (fr) |
EP (1) | EP0854729B2 (fr) |
JP (2) | JP4033489B2 (fr) |
KR (1) | KR19990045763A (fr) |
CN (1) | CN1211192A (fr) |
AT (1) | ATE261313T1 (fr) |
BR (1) | BR9610484A (fr) |
CA (1) | CA2232410C (fr) |
CZ (1) | CZ298460B6 (fr) |
DE (1) | DE69631835T3 (fr) |
DK (1) | DK0854729T3 (fr) |
EA (1) | EA199800208A1 (fr) |
ES (1) | ES2217325T5 (fr) |
HU (1) | HUP9901577A3 (fr) |
IL (1) | IL123720A (fr) |
MX (1) | MX9802128A (fr) |
NO (1) | NO320074B1 (fr) |
PL (1) | PL325604A1 (fr) |
PT (1) | PT854729E (fr) |
WO (1) | WO1997010844A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
ES2278446T3 (es) * | 1998-05-29 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Vacunas combinadas b/c contra la meningitis. |
BR0010130A (pt) | 1999-04-30 | 2002-06-04 | Chiron Spa | Antìgenos de neisseria conservados |
EP1179072A2 (fr) | 1999-05-19 | 2002-02-13 | Chiron S.P.A. | Compositions a base de combinaisons de neisseria |
AU3847801A (en) * | 2000-02-15 | 2001-08-27 | Intellivax International Inc | Proteosome influenza vaccine |
EP1419784A3 (fr) * | 2000-02-15 | 2004-08-25 | ID Biomedical Corporation of Quebec | Vaccins à base de protéosomes contre l'allergie, le cancer, les toxines |
ATE352631T1 (de) | 2000-02-28 | 2007-02-15 | Novartis Vaccines & Diagnostic | Heterologe expression von neisseria proteine |
MXPA03008154A (es) | 2001-03-09 | 2004-11-12 | Id Biomedical Corp Quebec | Novedoso adyuvante de vacuna de proteosoma-liposacarido. |
KR101140033B1 (ko) * | 2002-08-02 | 2012-05-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
GB0316560D0 (en) * | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
WO2005027964A1 (fr) * | 2003-09-15 | 2005-03-31 | Id Biomedical Corporation Of Quebec | Vaccin antirougeoleux sous-unitaire |
DE602004027940D1 (de) | 2003-10-22 | 2010-08-12 | Id Biomedical Corp Quebec | Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität |
EP1761276B1 (fr) | 2004-06-25 | 2013-07-24 | ID Biomedical Corporation of Quebec | Compositions et procedes de traitement de troubles neurologiques |
JP2008505114A (ja) * | 2004-06-30 | 2008-02-21 | アイディー バイオメディカル コーポレイション オブ ケベック | コロナウイルス感染を処置するためのワクチン組成物 |
US7552948B2 (en) | 2006-03-29 | 2009-06-30 | Tokai Rubber Industries, Ltd. | Quick connector |
TWI565713B (zh) * | 2006-08-07 | 2017-01-11 | 哈佛大學校長及研究員協會 | 蛋白基質疫苗以及該疫苗的製造與使用方法 |
CN101553246B (zh) * | 2006-08-07 | 2019-05-21 | 哈佛大学校长及研究员协会 | 蛋白质基质疫苗及这种疫苗的制备和给药方法 |
JP2010502425A (ja) * | 2006-08-30 | 2010-01-28 | ジーイー・ヘルスケア・バイオサイエンス・コーポレイション | 膜を評価するシステム及び方法並びに膜濾過装置 |
RU2477145C2 (ru) * | 2008-05-30 | 2013-03-10 | ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения |
WO2011031893A1 (fr) * | 2009-09-09 | 2011-03-17 | Matrivax Research & Development Corp. | Vaccins à base d'une matrice protéique et à immunogénicité renforcée |
JP6590916B2 (ja) * | 2014-09-24 | 2019-10-16 | ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーThe United States Of America As Represented By The Secretary Of The Navy | 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト |
AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
RU1522494C (ru) * | 1987-06-16 | 1994-11-15 | Научно-производственное объединение "Иммунопрепарат" | Способ получения инактивированной вакцины гриппа |
JPH01125328A (ja) * | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
US5145702A (en) * | 1988-09-19 | 1992-09-08 | Opta Food Ingredients, Inc. | Hydrophobic protein microparticles and preparation thereof |
AU640118B2 (en) * | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
US5102989A (en) * | 1991-03-15 | 1992-04-07 | Merck & Co., Inc. | Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells |
WO1994002626A1 (fr) * | 1992-07-20 | 1994-02-03 | Merck & Co., Inc. | Conjugues immunologiques d'epitopes de neutralisation principaux selectionnes specifiques du proteosome de la membrane externe et du vih |
US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
WO1995011700A1 (fr) * | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Emulsions submicroniques utilisees comme adjuvants de vaccin |
AU3847801A (en) * | 2000-02-15 | 2001-08-27 | Intellivax International Inc | Proteosome influenza vaccine |
-
1996
- 1996-09-18 PT PT96932269T patent/PT854729E/pt unknown
- 1996-09-18 CA CA002232410A patent/CA2232410C/fr not_active Expired - Lifetime
- 1996-09-18 BR BR9610484-8A patent/BR9610484A/pt not_active Application Discontinuation
- 1996-09-18 KR KR1019980702007A patent/KR19990045763A/ko not_active Application Discontinuation
- 1996-09-18 EA EA199800208A patent/EA199800208A1/ru unknown
- 1996-09-18 ES ES96932269T patent/ES2217325T5/es not_active Expired - Lifetime
- 1996-09-18 EP EP96932269A patent/EP0854729B2/fr not_active Expired - Lifetime
- 1996-09-18 PL PL96325604A patent/PL325604A1/xx unknown
- 1996-09-18 WO PCT/US1996/015002 patent/WO1997010844A1/fr active IP Right Grant
- 1996-09-18 JP JP51287597A patent/JP4033489B2/ja not_active Expired - Lifetime
- 1996-09-18 CZ CZ0081998A patent/CZ298460B6/cs not_active IP Right Cessation
- 1996-09-18 HU HU9901577A patent/HUP9901577A3/hu unknown
- 1996-09-18 AT AT96932269T patent/ATE261313T1/de not_active IP Right Cessation
- 1996-09-18 IL IL12372096A patent/IL123720A/en not_active IP Right Cessation
- 1996-09-18 DE DE69631835T patent/DE69631835T3/de not_active Expired - Lifetime
- 1996-09-18 CN CN96197616A patent/CN1211192A/zh active Pending
- 1996-09-18 US US09/043,529 patent/US6476201B1/en not_active Expired - Lifetime
- 1996-09-18 DK DK96932269T patent/DK0854729T3/da active
-
1998
- 1998-03-17 NO NO19981189A patent/NO320074B1/no not_active IP Right Cessation
- 1998-03-18 MX MX9802128A patent/MX9802128A/es unknown
-
2003
- 2003-10-24 JP JP2003365270A patent/JP2004099619A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0854729A4 (fr) | 2000-02-02 |
US20020164357A1 (en) | 2002-11-07 |
CN1211192A (zh) | 1999-03-17 |
DE69631835T2 (de) | 2005-02-10 |
KR19990045763A (ko) | 1999-06-25 |
WO1997010844A1 (fr) | 1997-03-27 |
CA2232410A1 (fr) | 1997-03-27 |
CZ81998A3 (cs) | 1998-10-14 |
JP4033489B2 (ja) | 2008-01-16 |
HUP9901577A3 (en) | 2000-03-28 |
HUP9901577A2 (hu) | 1999-08-30 |
IL123720A (en) | 2002-02-10 |
PT854729E (pt) | 2004-08-31 |
NO320074B1 (no) | 2005-10-17 |
EP0854729B2 (fr) | 2008-10-22 |
CZ298460B6 (cs) | 2007-10-10 |
PL325604A1 (en) | 1998-08-03 |
DE69631835T3 (de) | 2009-03-05 |
ES2217325T3 (es) | 2004-11-01 |
DK0854729T3 (da) | 2004-07-12 |
EP0854729A1 (fr) | 1998-07-29 |
EP0854729B1 (fr) | 2004-03-10 |
MX9802128A (es) | 1998-11-29 |
ES2217325T5 (es) | 2009-04-01 |
ATE261313T1 (de) | 2004-03-15 |
BR9610484A (pt) | 2001-09-11 |
IL123720A0 (en) | 1998-10-30 |
JP2000507913A (ja) | 2000-06-27 |
EA199800208A1 (ru) | 1998-10-29 |
JP2004099619A (ja) | 2004-04-02 |
DE69631835D1 (de) | 2004-04-15 |
US6476201B1 (en) | 2002-11-05 |
NO981189D0 (no) | 1998-03-17 |
NO981189L (no) | 1998-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2232410C (fr) | Procedes ameliores de production de vaccins polyvalents a sous-unites de proteosomes complexees de maniere non covalente | |
US6558677B2 (en) | Vaccine against gram negative bacteria | |
Frasch et al. | Outer membrane protein vesicle vaccines for meningococcal disease | |
CA2123355C (fr) | Preparation et utilisations de proteines de la membrane externe libre de los de cocci gram-negatifs | |
EP1286696B1 (fr) | Vaccin comprenant des vesicules de membrane externe utilise contre les maladies causees par le serogroupe a de i neisseria meningitidis /i et methode de preparation | |
US6638513B2 (en) | Neisseria meningitidis serogroup B Glycoconjugates | |
EP2482847B2 (fr) | Purification de vesicles bactériennes | |
EP3279313B1 (fr) | Souches de shigella à hyperblebs | |
BE1022875B1 (fr) | Compositions pour une immunisation contre staphylococcus aureus | |
EP0688206B1 (fr) | Systeme de liberation de vaccin et solution precurseur de longue conservation pour l'encapsulage a distance de principes actifs | |
JPS58162531A (ja) | 細菌莢膜由来の多糖類−蛋白質複合体の製法、その生成物およびそれを含有する免疫原組成物 | |
KR20060108739A (ko) | 개선된 내약성을 가지는 면역원성 조성물 중 소수성단백질의 제제 | |
Gotschlich | Meningococcal meningitis | |
AU751063B2 (en) | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines | |
Jiskoot et al. | Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes | |
Andersen et al. | Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response | |
Teerlink et al. | Synergistic effect of detergents and aluminium phosphate on the humoral immune response to bacterial and viral membrane proteins | |
WO2005042571A1 (fr) | Methode d'introduction d'antigenes dans des vesicules de la membrane externe de bacteries neisseria et preparations vaccinales associees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20160919 |